Compare EQ & ORIQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EQ | ORIQ |
|---|---|---|
| Founded | 2017 | 2024 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.4M | 89.2M |
| IPO Year | 2018 | 2025 |
| Metric | EQ | ORIQ |
|---|---|---|
| Price | $1.24 | $10.43 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $8.56 | N/A |
| AVG Volume (30 Days) | ★ 543.3K | 32.3K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $41,095,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.19 | $10.10 |
| 52 Week High | $6.20 | $10.45 |
| Indicator | EQ | ORIQ |
|---|---|---|
| Relative Strength Index (RSI) | 25.58 | 57.79 |
| Support Level | N/A | $10.34 |
| Resistance Level | $1.51 | $10.45 |
| Average True Range (ATR) | 0.11 | 0.01 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 0.00 | 73.91 |
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Origin Investment Corp I is a blank check company.